Since Cushing’s syndrome is characterized by elevated postprandial glucose levels, medications that lower these levels—such as DPPIV inhibitors, GLP1 receptor agonists, and rapid-acting insulin—may prove to be very beneficial. This evidence concerns the gene GLP1R and Cushing syndrome.